infection. 6 Although first infections increase the risk of adverse outcomes, second infections portend an even worse prognosis. 6 Recent data highlighted that some frequently used medications, such as proton pump inhibitors (PPIs), increase the risk of infections, whereas others, such as b-blockers, do not. [7] [8] [9] [10] [11] [12] However, prospective studies are needed to confirm and quantify these risks. 13 In addition, we frequently discharge patients from the hospital on antibiotics, such as norfloxacin, for spontaneous bacterial peritonitis (SBP) prophylaxis, and rifaximin for the prevention of recurrent hepatic encephalopathy. It remains uncertain if these medications alter the risk for future infections. Therefore, a particular focus on the infectious risks associated with medication use may result in altered strategies to improve outcomes. 14 Although the risk for subsequent infections and death is important in all cirrhotic patients, infections in liver transplant candidates are of particular interest. 15 As model for end-stage liver disease (MELD) scores at liver transplant continue to increase, 16 patients are waiting for transplant longer, with increased risk of infectious complications further highlighting the need to identify and change modifiable risk factors to maintain candidacy for transplant and increase survival.
To help identify patients at highest risk for subsequent infections, we prospectively followed up infected cirrhotic patients who were enrolled in the North American Consortium for the Study of End-Stage Liver Disease (NACSELD) for 6 months after hospital discharge for subsequent infections and their outcome. Before data analysis, we hypothesized that PPIs would increase the risk of subsequent infections, rifaximin and SBP prophylaxis would decrease the risk of subsequent infections, and b-blockers would not change the risk of subsequent infections.
Methods
The NACSELD consists of 12 hepatology referral sites throughout North America that prospectively collect data on hospitalized patients with cirrhosis who are admitted with a bacterial infection or develop one during hospitalization. This study was approved by all participating centers' Institutional Review Boards. Data were managed using Research Electronic Data Capture, which is based at Virginia Commonwealth University. Research Electronic Data Capture is a secure, web-based application that provides the following: (1) a portal for validated data entry; (2) an audit trail for ease of tracking data manipulation and export procedures; (3) an effortless data download into several statistical packages; and (4) the ability to import data from external sources.
Admitted cirrhotic patients who had or developed an infection were approached for consent. Cirrhosis was diagnosed by a combination of biochemical, radiologic, and endoscopic findings; or by liver biopsy. Infections were defined uniformly at all sites as described later.
Exclusion criteria included patients with additional independent risk for infection such as those with human immunodeficiency virus infection, prior solid organ transplant, or disseminated malignancies.
After informed consent was obtained, data collection included patient demographics; vital signs; baseline biochemistry, liver, and renal function; full blood count; and details of the infection including antibiotic treatment. Data collection also included intensive care unit admission, organ failure, liver transplantation, and length of hospitalization. Patients who were discharged without a liver transplant were followed up for up to 6 months to determine their outcome (alive with or without transplantation, or dead), and whether a subsequent infection that required hospitalization at any hospital had occurred. Follow-up data were acquired by study site coordinators from the patient or their caregiver by telephone. If an infection occurred during the 6-month follow-up period, records were obtained to validate the type of infection and the resistance pattern of the organism(s) diagnosed. During the telephone interview, patients' relevant medications (PPI, b-blocker, SBP prophylaxis, and rifaximin) also were updated. Patients' medications were known at discharge and at the 6-month follow-up evaluation; the differences between these 2 time points are detailed in Supplementary Tables 1 and 2 .
We defined infections according to standard criteria, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] as follows: (1) spontaneous bacteremia: positive blood cultures without a known source; (2) SBP: ascitic fluid polymorphonuclear cell count greater than 250/mL; (3) lower respiratory tract infections: new pulmonary infiltrate in the presence of the following: (a) at least one respiratory symptom (cough, sputum production, dyspnea, pleuritic pain), with (b) at least one finding on auscultation (rales or crepitation) or one sign of infection (core body temperature >38 C or <36 C, shivering, or leukocyte count >10,000/mm 3 or <4000/mm 3 ) in the absence of antibiotics; (4) Clostridium difficile infection: diarrhea with a positive C difficile assay; (5) soft-tissue/skin infection: fever with cellulitis; (6) urinary tract infection (UTI): urine white blood cell count greater than 15 per high-power field with either positive urine Gram stain or culture; (7) intra-abdominal infections: diverticulitis, appendicitis, cholangitis, and so forth, and bacterial enterocolitis; (8) other infections: diarrhea or dysentery with a positive stool culture for Salmonella, Shigella, Yersinia, Campylobacter, or pathogenic Escherichia coli, and (9) fungal infections as a special category.
The index infection was defined as the first infection that occurred during the hospitalization in which the patient consented to participate in the study. A second infection was defined as another infection that occurred during the same hospitalization in which the patient consented to participate. A subsequent infection was defined as an infection that occurred after discharge from the index-infection hospitalization. Infection resolution was defined as nonhospice hospital discharge.
Index and subsequent infections were diagnosed based on the same criteria. Drug-resistant organisms (DROs) were defined as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and quinolone-resistant gram-negative rods.
Statistical Analysis
Categoric data are presented as a percentage, continuous data are presented as the mean AE standard deviation, and discrete data are presented as the median with an interquartile range. Categoric variable analysis was performed with the chi-square test, and group comparisons were performed with either a 2-sample t test or a 1-way analysis of variance (!3 groups were compared). Group comparisons for discrete data were performed with the Wilcoxon rank-sum test (Mann-Whitney U test) for 2 groups or the Kruskal-Wallis for 2 or more groups. For all statistical analyses, SAS 9.1 (SAS Institute Inc, Cary, NC) was used, and a P value less than .05 was considered statistically significant.
Multivariate logistic regression modeling using stepwise elimination was used. The dependent variable was a subsequent infection within 6 months of hospital discharge after an index infection. Variables read into stepwise regression included age, sex, alcoholic etiology, laboratory values at admission of index hospitalization, Child-Turcotte-Pugh (CTP) score (at index hospitalization), and separately serum albumin and sodium; second infection during the index hospitalization; the type of infection (SBP vs non-SBP infection); number of infections in the 6 months before index hospitalization; and medication use at the 6-month follow-up evaluation (PPI, rifaximin, SBP prophylaxis, and nonselective b-blocker use). All final models only included variables that remained statistically significant (P < .05) with the exception of MELD score, which was forced into the final model.
Results
The NACSELD enrolled 337 cirrhotic inpatients with infections. During the index hospitalization 68 patients died and 14 patients underwent liver transplantation ( Figure 1 ). Of the 255 patients who were discharged without transplant, 22 had not reached 6 months of follow-up and 45 were lost to follow-up. Six-month follow-up evaluations with infection outcomes reported were available for the remaining 188 patients; 27% (51 of 188) died, 14% (26 of 188) received a transplant, and 59% (110 of 188) experienced transplant-free survival. During follow-up, 45% (84 of 188) of patients experienced at least one subsequent infection requiring hospitalization (90 total infections). This occurred in 6% in less than 2 weeks, in 28% in 2 to less than 6 weeks, in 17% in 6 weeks to less than 3 months, in 28% in 3 to 6 months, and in 21% in an unknown time after discharge. Patients with second infections during their index hospitalization who survived to the 6-month follow-up evaluation had a 54% (19 of 35) risk of a subsequent infection. Also, as shown in Table 1 , there were no significant differences regarding demographics, etiology of cirrhosis, liver tests, MELD score, and CTP score between those who developed a subsequent infection and those who did not. There was a tendency for age to be greater in those who developed a subsequent infection (57.7 vs 55.1 y; P ¼ .06). Infection type was not statistically significantly different between the index and subsequent infection (Table 2) . Similarly, there was no difference between culture results of index and subsequent infections. Additional illness severity-related factors from the index hospitalization were analyzed separately (Table 3) 
Despite the similar distribution of infection types, the vast majority of subsequent infections were different than the primary infection (74%). Figure 2 details the 26% (22 of 84) of patients with subsequent infections at the same site by type; C difficile had the highest risk (40%; 2 of 5), followed by UTIs (32%; 9 of 28), and skin/ soft tissue infections (22%; 2 of 9). Although 33% (4 of 12) of patients with other infections had subsequent other infections, we cannot confirm these occurred in the exact same location.
DROs were equally likely in patients with index (16%; 34 of 188) and subsequent (17%; 14 of 84) infections (Supplementary Table 3 ). However, DROs were found most commonly in patients with SBP as a subsequent infection than as an index infection (42% [8 of 19] vs 7% [3 of 46]; P ¼ .02). The risk of a DRO in subsequent infections was lower in patients with UTIs (11%; 3 of 28), and spontaneous bacteremia (7%; 1 of 14).
Medication utilization rates at hospital discharge were confirmed at 6 months of follow-up evaluation and differed between patients with and without subsequent infections. Patients with subsequent infections had a higher rate of PPI (72.6% vs 52.9%; P ¼ .006), rifaximin (52.4% vs 27.9%; P < .001), and SBP prophylaxis (53.6% vs 21.2%; P < .001) use, and a similar rate of nonselective b-blocker use (31.0% vs 39.4%; P ¼ NS) than those not prescribed these medications. However, patients taking rifaximin had higher index admission MELD scores (20 vs 18; P ¼ .04) and higher index admission CTP scores (10 vs 9; P ¼ .03) than patients not prescribed the medication. On the other hand, MELD scores were not significantly different during the index admission between PPI and SBP prophylaxis users and nonusers, but in both groups the medication users had higher CTP scores (PPI: 10 vs 9; P ¼ .02; SBP: 10 vs 9; P ¼ .03) than nonusers, respectively. Nonselective b-blocker use was not associated with any marker of disease severity. Although the unadjusted risk of all types of subsequent infections was higher in patients taking SBP prophylaxis, rifaximin, and PPIs, the individual types of infections did not statistically significantly differ between patients, as highlighted in Supplementary Table 4 . Of note, the risk of SBP was similar between patients whose index hospitalization was for recurrent SBP, and those with recurrent SBP during the 6-month follow-up period (22% [2 of 9] vs 11% [5 of 45]; P ¼ .6).
The multivariate stepwise logistic regression model (Table 4) We did experience an 18% loss to follow-up evaluation despite multiple attempts to find all patients. We did not find any statistically significant differences in MELD score, age, or use of medications studied between those with and those without follow-up evaluation. However, patients who were lost to follow-up evaluation had a lower CTP score than those with follow-up evaluation (8.7 AE 2.4 vs 10.0 AE 2.0; P ¼ .002).
Discussion
In our multicenter, prospective study, we found that cirrhotic patients discharged after adequate control of their index infection remained at high risk of subsequent infections. The subsequent infection usually was different from the infection at index hospitalization: the type of subsequent infection was different from the primary infection 74% of the time, and 17% were caused by DROs. This risk was independent of liver disease severity, possibly owing to the relatively high median MELD and CTP scores seen in our patients, and was associated with type of index infection, older age, PPI use, and SBP prophylaxis.
In noncirrhotic patients, reports in the literature consistently documented an increased risk of death after discharge in patients with sepsis. 18, 19 Only one small study has shown an increased longer-term risk of subsequent infections in discharged noncirrhotic intensive care unit patients. 20 Our multicenter study extended this observation to cirrhotic patients. This is important because the subsequent infection risk may be even greater in patients with cirrhosis than in patients without cirrhosis because of the increased bacterial translocation that is often coupled to small intestinal bacterial overgrowth (SIBO), dysbiosis, and immunodeficiency. 3, 21 Cirrhosis not only increases access of intestinal bacteria to the portal circulation, but these translocated bacteria and resultant cytokines are even less likely to be cleared by the liver because of impaired reticuloendothelial cell phagocytosis and increased collateral blood flow. Patients with cirrhosis also are immunodeficient, 3 thereby impairing the host's ability to clear translocated bacteria. Several known mechanisms of immunodeficiency in cirrhosis include but are not limited to polymorphonuclear impairment in phagocytosis and migration to infected sites; low complement and interleukin levels; altered macrophage Fc biding, adhesion, and function; opsonization impairment; and altered antibody-mediated bactericidal capability. 3 It is less clear how immune regulation may be altered in the longer term once infection occurs in a cirrhotic host. During severe infection, the systemic inflammatory response syndrome is activated, which involves innate immune activation and secretion of proinflammatory cytokines. 22 During infection or its resolution, the compensatory anti-inflammatory response syndrome (CARS) also may be activated. [23] [24] [25] [26] CARS can include down-regulation of antigen presentation, macrophage deactivation, production of anti-inflammatory cytokines, and ultimate anergy. Of note, changes that result from CARS increase susceptibility to other pathogens. The duration of these changes that may result in immunologic paralysis remains unknown. Although we did not directly investigate these risks from an immunologic standpoint, the continued susceptibility to infections, especially those unrelated to the index infection type, points toward an impaired immune response as the likely culprit.
In addition to an inherent increased risk to subsequent infection posed by the index infection, medications may modulate this propensity further. This prospective study has confirmed most of the prior retrospective studies documenting no alteration in the risk of infection with nonselective b-blocker administration. [10] [11] [12] 27 Furthermore, our data confirm prior work showing PPIs are associated with an increased risk of subsequent infections in cirrhotic patients. 7, [28] [29] [30] [31] Direct effects of PPIs on the immune system include blockade of the oxidative burst of neutrophils through inhibition of the Hþ pump required for the rapid release of toxic reactive oxygen species, inhibition of interleukin 8 production decreases inflammatory cell recruitment, and limitation of oxidation. 32 In addition, indirect effects of PPIs include exacerbation of the cirrhotic host's predisposition to SIBO and preferential growth inhibition of nonpathogenic microorganisms, leaving room for potential pathogens. 33 Our data and others' data documenting association with the direct and indirect effects of PPIs on immune function and SIBO make us believe there is a causal relationship between PPIs and subsequent infections.
Although much is known about the increased infectious risks of cirrhotic patients taking PPIs, it is less clear how SBP prophylaxis may be associated with infectious outcomes. It is more likely that the need for this class of medications, rather than the medications themselves, may be associated with subsequent infections. A higher CTP score was seen in patients on SBP prophylaxis, which may explain the risk for subsequent infections. Alternatively, the simple need for SBP prophylaxis may indicate a high risk of bacterial translocation or selection of microbiota resistant to the prophylaxis agent over time. This potential selection of resistant pathogens also could explain why the first SBP episode was protective against subsequent infections whereas SBP prophylaxis was associated with a higher risk of subsequent infections.
We not only documented an increased risk of subsequent infections in cirrhotic patients after hospital discharge with an infection, but a significant risk that the subsequent infection will be caused by a DRO in patients with SBP. Although the overall DRO rates were similar between index (16%) and subsequent (17%) infections, there was a high rate of DROs in patients whose subsequent infection was SBP (42%). Fortunately, there was a low risk of recurrent SBP in patients whose first infection was SBP. Others have seen the disturbing trend in cirrhotic patients in single-center studies that more infections are being caused by DRO. 4, [34] [35] [36] [37] We hypothesize that the use, and possible overuse, of antibiotics in the hospital and outpatient setting likely has resulted in this increase. Although antibiotic prophylaxis to prevent recurrent SBP and infections after variceal hemorrhage has been very successful; 38, 39 with the increased need to develop infection prevention strategies, it will be critical to find nonantibiotic means of preventing infections in patients with cirrhosis to avoid an even higher prevalence of DRO. If these findings are replicated, alternative infection prevention strategies will need to be sought.
Although bolstered by the prospective data collection, large sample size, and multicenter approach, exact dates of subsequent infections were not collected, limiting our ability to perform a time-to-event analysis. Another limitation included our 18% loss to follow-up evaluation. The only difference between the 2 groups was a lower CTP score among those who were lost to follow-up evaluation than those who were followed up. Given similar MELD scores, medication use, and other clinical criteria, it is unlikely that this small difference would have made an appreciable alteration in the ultimate outcome of the study.
In conclusion, infected cirrhotic patients discharged from the hospital have a 41% risk of death or liver transplantation within 6 months. In transplant-free survivors, the risk of subsequent infections remains high at 45%. The risk of subsequent infections cannot be predicted by just liver severity indices, but is increased in older patients with non-SBP index infections, especially if they are taking PPIs or SBP prophylaxis. Given the association with PPI use, its indication should be evaluated critically in all patients. In patients who require SBP prophylaxis, further evaluation of bacterial species and a better understanding of the disease states' association with subsequent infections is needed. Because these infections represent a continued potential source of morbidity and mortality not adequately managed by current medications, novel (preferably non-antibioticbased) infection prevention strategies are needed for cirrhotic patients who survive an index hospitalization with infection.
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